Monte Rosa Therapeutics Inc. (NASDAQ: GLUE) saw its stock skyrocket over 30% in premarket trading on Monday after announcing a global exclusive development and commercialization agreement with pharmaceutical giant Novartis AG (NYSE: NVS) for its VAV1 MGDs, including MRT-6160. The deal grants Novartis worldwide rights to develop and commercialize the drug, which is currently in Phase 1 clinical trials for immune-mediated conditions. The partnership highlights the potential of MRT-6160, a novel drug targeting a key signaling protein involved in immune responses, and its promising future in treating various immune-related diseases.